Friday, February 27, 2026 1:32:15 PM
At times like these I need to console myself with a sober look at a worst case scenario. If that represents a reasonable floor, it's easier to relax about all this.
So what is that scenario? Denner gives up on thinking he can actually make a profit on this ill-conceived speculation, and looks to salvage some value.
There has to be somebody out there who can do simple math. Assuming a really poor trajectory of revenues, all things considered, you still have to be able to see cash flow positive out to 2039 with expenses as skinny as they are now. Maybe worst case, that's $20mm this year, ramping up to $100mm by say 2033, and then staying there until 2039 as the US winds down while Europe keeps growing.
So that somebody looks at this and says, "Shit, I don't need to spend $100mm on OpEx... this is a simple bolt-on, I can fire almost everybody, I have to be able to get that incremental OpEx for me down to $40mm -- $50mm worst case." So now that somebody can add $50mm in cash flow onto the existing stream. $70mm ramping to $150mm. Some taxes will have to be paid, as the NOL won't be fully utilizable.
Still, that has to support a $1bn price tag at a minimum. Call it $50 per share. Is the worst case here worse than that?
So what is that scenario? Denner gives up on thinking he can actually make a profit on this ill-conceived speculation, and looks to salvage some value.
There has to be somebody out there who can do simple math. Assuming a really poor trajectory of revenues, all things considered, you still have to be able to see cash flow positive out to 2039 with expenses as skinny as they are now. Maybe worst case, that's $20mm this year, ramping up to $100mm by say 2033, and then staying there until 2039 as the US winds down while Europe keeps growing.
So that somebody looks at this and says, "Shit, I don't need to spend $100mm on OpEx... this is a simple bolt-on, I can fire almost everybody, I have to be able to get that incremental OpEx for me down to $40mm -- $50mm worst case." So now that somebody can add $50mm in cash flow onto the existing stream. $70mm ramping to $150mm. Some taxes will have to be paid, as the NOL won't be fully utilizable.
Still, that has to support a $1bn price tag at a minimum. Call it $50 per share. Is the worst case here worse than that?
"The biggest obstacles to our progress exist within our own lives in the form of cowardice and the tendency to give up. Breaking through these barriers will unleash a surging wave of change." -- Daisaku Ikeda
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
